文献速递肝病

他汀类药物使用与原发性硬化性胆管炎患者结局改善相关

Statin Use Is Associated With Improved Outcomes of Patients With Primary Sclerosing Cholangitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-11-15

瑞典一项基于人群的队列研究纳入2005至2014年2914例原发性硬化性胆管炎(PSC)合并溃疡性结肠炎或克罗恩病患者,随访至2016年。他汀使用与全因死亡风险降低(HR 0.68;95%CI 0.54-0.88)及死亡或肝移植风险降低(HR 0.50;95%CI 0.28-0.66)相关;熊去氧胆酸暴露与死亡率降低无关(HR 1.04;95%CI 0.87-1.25)。

要点

  • 他汀使用与PSC患者全因死亡风险降低相关(HR 0.68;95%CI 0.54-0.88)。
  • 他汀使用与死亡或肝移植风险降低相关(HR 0.50;95%CI 0.28-0.66)。
  • 熊去氧胆酸暴露与死亡率降低无关(HR 1.04;95%CI 0.87-1.25)。

核心结论

  • 在瑞典基于人群的PSC队列中,他汀和硫唑嘌呤使用与死亡及死亡或肝移植风险降低相关。
  • 熊去氧胆酸暴露与死亡率降低无关。

研究设计与样本

  • 瑞典基于人群的队列研究,纳入2005年至2014年PSC合并溃疡性结肠炎或克罗恩病患者2914例,随访至2016年。
  • 数据来自患者登记、处方药登记、死亡证明登记和癌症登记,计算死亡、肝移植、食管静脉曲张出血和癌症风险与药物暴露的关系。

主要发现

  • PSC诊断时平均年龄41.4岁(四分位距[IQR] 25.6-56.1岁),总随访11769人年,3.4%患者接受肝移植,19.9%死亡。
  • 药物暴露比例:熊去氧胆酸60.2%,5-氨基水杨酸74.4%,硫唑嘌呤或巯嘌呤类33.7%,他汀13.9%。
  • 他汀使用与全因死亡风险降低相关(HR 0.68;95%CI 0.54-0.88),与死亡或肝移植风险降低相关(HR 0.50;95%CI 0.28-0.66)。
  • 硫唑嘌呤使用与死亡率降低相关(HR 0.66;95%CI 0.52-0.84),与死亡或肝移植风险降低相关(HR 0.65;95%CI 0.50-0.83)。
  • 熊去氧胆酸暴露不影响死亡率(HR 1.04;95%CI 0.87-1.25)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is increasing evidence that statins can benefit patients with chronic liver diseases, but their effects have not been studied in patients with primary sclerosing cholangitis (PSC). We performed a nationwide study in Sweden to determine the effects of exposure to drugs, including statins, in patients with PSC. METHODS: We studied a population-based cohort of patients in Sweden with PSC and concomitant ulcerative colitis or Crohn's disease from 2005 through 2014 (n = 2914), followed through 2016. We collected analyzed data from the patient register, the prescribed drug register, the death certificate register and the cancer register. We calculated risk or death, liver transplantation, bleeding of esophageal varices, and cancer in relation to drug exposure. RESULTS: The mean age of patients at the time of diagnosis with PSC was 41.4 years (inter-quartile range [IQR], 25.6-56.1 years). The total follow-up time was 11769 person-years, during which 3.4% of patients received liver transplants and 19.9% died. Proportions of patients exposed to drugs were: ursodeoxycholic acid, 60.2%; 5-aminosalicylic acid, 74.4%; azathioprine or mercaptopurins, 33.7%; and statins, 13.9%. Statin use was associated with a reduced risk of all-cause mortality (hazard ratio [HR], 0.68; 95% CI, 0.54-0.88) and death or liver transplantation (HR, 0.50; 95% CI, 0.28-0.66). Use of azathioprine was also associated with reduced mortality (HR, 0.66; 95% CI, 0.52-0.84) and risk of death or liver transplantation (HR, 0.65; 95% CI, 0.50-0.83). Exposure to ursodeoxycholic acid did not affect mortality (HR, 1.04; 95% CI, 0.87-1.25). CONCLUSION: In a population-based cohort of patients in Sweden with PSC, we associated use of statins and azathioprine with decreased risks of death and death or liver transplantation. Exposure to ursodeoxycholic acid was not associated with reduced mortality.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Stokkeland K, Höijer J, Bottai M, et al. Statin Use Is Associated With Improved Outcomes of Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2018. PMID: 30448601. doi:10.1016/j.cgh.2018.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。